An ear­ly ar­rival among '17 biotech IPOs, Anap­tys­Bio keeps to its range in suc­cess­ful $75M play

Anap­tys­Bio has upped its shares but still man­aged to hit the mid-point of its IPO range, rais­ing $75 mil­lion.

The suc­cess­ful out­ing marks an en­cour­ag­ing start to the year for biotech IPOs, which have been in rough ter­rain af­ter a year of ups and downs on Wall Street. Right now, a mid-range IPO looks pret­ty good. And it per­haps bodes well for the ini­tial line­up of biotech com­pa­nies look­ing to start the year with an IPO raise.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.